Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 4/20 | 0.51 |
| ▸ | MPO | P05164 | 3/20 | 0.43 |
| ▸ | CNR2 | P34972 | 5/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.42 |
| ▸ | CNR1 | P21554 | 3/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29199466 | 0.95 | SLC9A1 (0.50) | SLC9A1MPOCNR2TLR8PDE4A | |
| SCHEMBL29199475 | 0.88 | SLC9A1 (0.47) | SLC9A1CNR2CNR1GRM2 | |
| SCHEMBL18487132 | 0.81 | ALDH1A1 (0.43) | SLC9A1MPOCNR2CNR1 | |
| SCHEMBL570746 | 0.80 | SLC9A1 (0.44) | SLC9A1GRM2 | |
| SCHEMBL570412 | 0.77 | TDO2 (0.39) | — | |
| SCHEMBL3326163 | 0.70 | GRM2 (0.47) | SLC9A1CNR2CNR1GRM2 | |
| SCHEMBL1176401 | 0.69 | LMNA (0.36) | — | |
| SCHEMBL4589328 | 0.69 | CNR1 (0.50) | SLC9A1MPOCNR2TLR8CNR1 | |
| SCHEMBL3663636 | 0.68 | ALDH1A1 (0.52) | — | |
| SCHEMBL28905062 | 0.68 | SLC9A1 (0.41) | SLC9A1CNR2TLR8CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1622866-B1 | AMINOPROPANOL DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATORS | NOVARTIS AG (CH) | 2012-07-25 | — | — | EP | disclosed |
| US-7825260-B2 | Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators | NOVARTIS AG (CH) | 2010-11-02 | — | — | US | disclosed |
| CN-1809531-B | Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators | NOVARTIS AG | 2010-05-26 | — | — | CN | disclosed |
| US-20060211656-A1 | Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators | NOVARTIS AG (CH) | 2006-09-21 | — | — | US | disclosed |
| CN-1809531-A | Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators | NOVARTIS AG (CH) | 2006-07-26 | — | — | CN | disclosed |
| EP-1622866-A1 | AMINOPROPANOL DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATORS | Novartis AG (CH) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004096757-A1 | AMINOPROPANOL DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATORS | NOVARTIS AG (CH) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211656-A1 | Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators | S1PR1, S1PR3, S1PR2 | SLC9A1 2876/4885MPO 4883/4885CNR2 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.